These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 9552430)
21. A protocol for the classification of wet mass in extrusion-spheronization. Gao Y; Hong Y; Xian J; Lin X; Shen L; Zhang X; Zhang N; Feng Y Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):996-1005. PubMed ID: 23563104 [TBL] [Abstract][Full Text] [Related]
22. Alginate-based pellets prepared by extrusion/spheronization: a preliminary study on the effect of additive in granulating liquid. Sriamornsak P; Nunthanid J; Luangtana-anan M; Puttipipatkhachorn S Eur J Pharm Biopharm; 2007 Aug; 67(1):227-35. PubMed ID: 17276664 [TBL] [Abstract][Full Text] [Related]
23. Use of cellulose ether containing excipients with microcrystalline cellulose for the production of pellets containing metformin hydrochloride by the process of extrusion-spheronization. Gouldson MP; Deasy PB J Microencapsul; 1997; 14(2):137-53. PubMed ID: 9132466 [TBL] [Abstract][Full Text] [Related]
24. Multivariate optimization of formulation and process variables influencing physico-mechanical characteristics of site-specific release isoniazid pellets. Pund S; Joshi A; Vasu K; Nivsarkar M; Shishoo C Int J Pharm; 2010 Mar; 388(1-2):64-72. PubMed ID: 20035851 [TBL] [Abstract][Full Text] [Related]
25. Production and characterization of pellets using Avicel CL611 as spheronization aid. Puah SY; Yap HN; Chaw CS Drug Dev Ind Pharm; 2014 Mar; 40(3):418-24. PubMed ID: 23480532 [TBL] [Abstract][Full Text] [Related]
26. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization. Goyanes A; Martínez-Pacheco R Drug Dev Ind Pharm; 2015 Mar; 41(3):362-8. PubMed ID: 24279425 [TBL] [Abstract][Full Text] [Related]
27. The influence of plate design on the properties of pellets produced by extrusion and spheronization. Michie H; Podczeck F; Newton JM Int J Pharm; 2012 Sep; 434(1-2):175-82. PubMed ID: 22659150 [TBL] [Abstract][Full Text] [Related]
28. The influence of model drugs on the preparation of pellets by extrusion/spheronization: II. Spheronization parameters. Tomer G; Podczeck F; Newton JM Int J Pharm; 2002 Jan; 231(1):107-19. PubMed ID: 11719019 [TBL] [Abstract][Full Text] [Related]
29. Alternative extrusion-spheronization aids. Jain SP; Singh PP; Amin PD Drug Dev Ind Pharm; 2010 Nov; 36(11):1364-76. PubMed ID: 20521907 [TBL] [Abstract][Full Text] [Related]
30. Use of chitosan-alginate as alternative pelletization aid to microcrystalline cellulose in extrusion/spheronization. Charoenthai N; Kleinebudde P; Puttipipatkhachorn S J Pharm Sci; 2007 Sep; 96(9):2469-84. PubMed ID: 17286294 [TBL] [Abstract][Full Text] [Related]
31. Differences in characteristics of pellets prepared by different pelletization methods. Häring A; Vetchý D; Janovská L; Krejcová K; Rabisková M Drug Dev Ind Pharm; 2008 Mar; 34(3):289-96. PubMed ID: 18363144 [TBL] [Abstract][Full Text] [Related]
32. [Influence of the speed of spheronization on the physical properties and dissolution availability of theophylline minigranules prepared by extrusion-spheronization]. Rahman L; Gaudy D; Bataille B; Jacob M; Puech A J Pharm Belg; 1991; 46(6):389-95. PubMed ID: 1783973 [TBL] [Abstract][Full Text] [Related]
33. Extrusion/spheronization--effect of moisture content and spheronization time on pellet characteristics. Iyer RM; Augsburger LL; Pope DG; Shah RD Pharm Dev Technol; 1996 Dec; 1(4):325-31. PubMed ID: 9552316 [TBL] [Abstract][Full Text] [Related]
34. Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid. Krueger C; Thommes M Pharm Dev Technol; 2013 Feb; 18(1):225-35. PubMed ID: 22780876 [TBL] [Abstract][Full Text] [Related]
35. Optimization of melt pelletization in a high shear mixer. Bukovec P; Kroselj V; Turk S; Vrecer F Int J Pharm; 2009 Nov; 381(2):192-8. PubMed ID: 19580855 [TBL] [Abstract][Full Text] [Related]
36. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique I. Formulation and process variables affecting pellet characteristics. Cheboyina S; Wyandt CM Int J Pharm; 2008 Jul; 359(1-2):158-66. PubMed ID: 18499369 [TBL] [Abstract][Full Text] [Related]
37. The influence of drug solubility and particle size on the pellet formulation in a rotoprocessor. Krejcová K; Rabisková M; Vetchý D; Polásek E; Tomásek V; Prokopová A Drug Dev Ind Pharm; 2006 Jun; 32(5):585-93. PubMed ID: 16720413 [TBL] [Abstract][Full Text] [Related]
38. The influence of liquid binder on the liquid mobility and preparation of spherical granules by the process of extrusion/spheronization. Boutell S; Newton JM; Bloor JR; Hayes G Int J Pharm; 2002 May; 238(1-2):61-76. PubMed ID: 11996811 [TBL] [Abstract][Full Text] [Related]
39. The influence of chitosan and sodium alginate and formulation variables on the formation and drug release from pellets prepared by extrusion/spheronisation. Chatchawalsaisin J; Podczeck F; Newton JM Int J Pharm; 2004 May; 275(1-2):41-60. PubMed ID: 15081137 [TBL] [Abstract][Full Text] [Related]
40. Control of drug release by incorporation of sorbitol or mannitol in microcrystalline-cellulose-based pellets prepared by extrusion-spheronization. Goyanes A; Souto C; Martínez-Pacheco R Pharm Dev Technol; 2010 Dec; 15(6):626-35. PubMed ID: 20148708 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]